Healthcare (Prescription Drugs)

in committee · New Jersey · General Assembly Jan 13, 2026

A 669: Requires electric public utility to reimburse residential customer for cost of food and prescription medicine spoiled or compromised as a result of sustained electric service outage.

This bill requires New Jersey electric utilities to reimburse residential customers for spoiled food and compromised prescription medicine caused by sustained power outages lasting over 48 hours after major events (like storms). Customers can receive up to $500 for spoiled food (with proof like receipts) or up to $1,000 for compromised medicine (with pharmacy documentation). Utilities must create an online reimbursement system within 90 days, processing claims within 30 days of submission. The bill directly affects residential electricity customers experiencing extended outages and applies to all electric utilities in New Jersey.

Topics ✓ HealthcareSupports HealthcareReimburses for compromised prescription medicine, ensuring access to essential healthcare during outages, directly protecting patient access to critical medications.85% confidence

Sub-Topics Prescription Drugs

Track

in committee · New Jersey · General Assembly Jan 13, 2026

A 1734: Requires pharmacies to provide 90 days notice to municipality prior to closure.

This bill requires pharmacies to provide written notice to their local municipality at least 90 days before closing, in addition to existing state and federal notification requirements. It directly affects pharmacy owners and local municipalities by giving communities advance warning of potential pharmacy closures. The key provision mandates that pharmacy permit holders or their authorized representatives send this written notice to the municipality's governing board 90 days prior to closure. The bill also directs the State Board of Pharmacy to create implementing rules, but does not change current state or federal closure notification processes.

Topics ✓ HealthcareSupports HealthcareRequires 90-day notice for pharmacy closures, maintaining community access to essential healthcare services and preventing sudden loss of medication access.85% confidence

Sub-Topics Prescription Drugs

Track

in committee · New Jersey · General Assembly Jan 13, 2026

A 249: Prohibits pre-approval or precertification of medical tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.

This bill (A 249) prohibits health insurers, pharmacy benefits managers, and state health programs (like the State Health Benefits Program) from requiring pre-approval or precertification for covered medical tests, procedures, or prescription drugs. It applies when a licensed healthcare provider prescribes the service or drug, and it is already covered under the health or prescription drug plan. The law directly affects patients seeking covered care by removing bureaucratic delays caused by insurance company review processes. Key provisions eliminate requirements for prior authorization on covered services, ensuring payment is processed without insurer-imposed delays. The bill takes effect immediately for plans issued or purchased on or after the effective date.

Topics ✓ HealthcareSupports HealthcareRemoves pre-approval barriers for covered healthcare services, improving patient access to existing insurance benefits without restricting coverage.95% confidence

Sub-Topics Insurance Prescription Drugs

Track

in committee · New Jersey · General Assembly Jan 13, 2026

A 2537: Prohibits prior authorization when prescribing certain drugs.

This New Jersey bill (A 2537) prohibits health insurance carriers from requiring prior authorization when a doctor prescribes an interchangeable drug if the brand-name drug or its generic version is unavailable. It directly affects patients, doctors, and insurers by removing a common administrative barrier that delays access to certain medications. The law defines "carriers" as insurance companies, health plans, or entities managing state health programs, and mandates they cannot block prescriptions for interchangeable drugs under the specified availability conditions. The bill takes effect immediately upon enactment.

Topics ✓ HealthcareSupports HealthcareBill prohibits prior authorization for interchangeable drugs when brand/generic unavailable, directly improving patient access to medications by removing administrative delays.95% confidence

Sub-Topics Insurance Prescription Drugs

Track

in committee · New Jersey · General Assembly Jun 4, 2026

A 1510: Improves access to lower cost generic and biosimilar drugs and revises certain requirements regarding dispensing of biosimilar drugs by pharmacies.*

This bill requires New Jersey's Medicaid managed care organizations to automatically include lower-cost generic and biosimilar drugs on their formularies with better cost-sharing (like lower copays) when they are cheaper than the original brand drugs. It directly affects insurers managing Medicaid plans and their enrollees, ensuring patients pay less for equivalent treatments. Key provisions mandate that if a generic drug's price is lower than its reference brand at launch, insurers must list it with favorable cost-sharing and remove barriers like prior authorization. The bill does not force insurers to stop covering brand drugs but ensures cheaper alternatives are prioritized for cost savings. It applies only when cheaper options are available and respects medical appropriateness decisions by insurers.

Topics ✓ Budget & TaxesSupports Budget & TaxesMandates Medicaid managed care to use cheaper drugs, reducing state spending on pharmaceuticals and promoting fiscal responsibility within Medicaid budget management.85% confidence ✓ HealthcareSupports HealthcareMandates lower-cost drug inclusion in Medicaid formularies, reducing patient copays and improving access to affordable treatments.95% confidence

Sub-Topics Government Spending Medicaid Prescription Drugs

Track

in committee · New Jersey · General Assembly Jan 13, 2026

A 3554: Removes exception of self-insured health benefits plans from law concerning pharmacy benefits managers.

This New Jersey bill (A-3554) removes an exemption that previously allowed self-insured employer health plans (covered under federal law) to be excluded from state regulations governing pharmacy benefits managers (PBMs). It directly affects self-insured health plans by requiring them to comply with the state's existing PBM rules, such as transparency and fair pricing standards. The bill also mandates a report to state legislators examining how a 2020 U.S. Supreme Court ruling (Rutledge v. PCMA) impacts these regulations. The policy change applies to all health plans renewed or initiated after the effective date, ensuring consistent oversight of PBMs across all plan types.

Topics ✓ HealthcareSupports HealthcareRequires self-insured health plans to comply with state PBM transparency and pricing rules, protecting consumers and strengthening regulatory oversight.95% confidence ✓ Labor & EmploymentSupports Labor & EmploymentRequires self-insured employer health plans to comply with state PBM transparency/fair pricing rules, strengthening employee health benefits access under employment standards.90% confidence

Sub-Topics Prescription Drugs

Track

in committee · New Jersey · General Assembly Jan 13, 2026

A 1785: Establishes insulin assistance program.

This bill establishes a state-run insulin assistance program under New Jersey's Department of Human Services. It provides free insulin and related supplies to uninsured individuals who prove financial inability to pay for prescribed insulin, through participating pharmacies that are fully reimbursed by the state. To qualify, individuals must apply to DHS, lack health insurance, and demonstrate financial need; approved participants receive coverage for 90-day periods with the option to reapply. The program operates only if funds are available and requires pharmacies to register with the state to participate.

Topics ✓ HealthcareSupports HealthcareProvides free insulin to uninsured, low-income residents via state program, expanding access to essential medication and addressing coverage gaps.95% confidence

Sub-Topics Insurance Prescription Drugs

Track

in committee · New Jersey · General Assembly Feb 19, 2026

A 4184: Prohibits excessive increases in prices charged for essential off-patent and generic prescription drugs and biological products.

This bill prohibits manufacturers and distributors from raising prices excessively on essential generic prescription drugs and biological products after their patents expire. It targets drugs that are widely used, lack patent protection, and are critical for treating serious health conditions (like life-threatening or chronic illnesses), with price hikes exceeding 50% within a year for drugs costing over $80 for a 30-day supply. The Director of Consumer Affairs monitors prices and must notify the Attorney General if a price increase meets these thresholds, requiring manufacturers to explain the increase within 45 days. The law aims to prevent unjustified price spikes that leave patients with no affordable alternatives, directly affecting drug companies, pharmacies, and patients using these essential medications.

Topics ✓ HealthcareSupports HealthcarePrevents excessive price hikes on essential generic drugs, improving patient access to critical medications and protecting against cost-driven barriers in healthcare.95% confidence

Sub-Topics Prescription Drugs

Track

died · New Jersey · General Assembly Jan 13, 2026

A 3359: Regulates provision of pharmaceutical services in nursing homes.

This bill (A 3359) requires New Jersey nursing homes to have specific pharmacy staffing and oversight structures to improve medication management. It mandates each facility to employ a consultant pharmacist (not affiliated with the facility's pharmacy staff), a provider pharmacist or in-house pharmacy director, and an interdisciplinary pharmacy committee that meets quarterly to review medication use. The committee must include the facility administrator, nursing staff representative, and consultant pharmacist, with records maintained of all meetings. The bill also adds a conflict-of-interest requirement, requiring consultant pharmacists to attest they have no ties to the facility’s pharmacy leadership. *Note: The bill was withdrawn on January 13, 2026, as it was already codified in P.L.2025, c.294.*

Topics ✓ HealthcareSupports HealthcareMandates pharmacy oversight structures to improve medication management in nursing homes, enhancing patient safety and care quality per bill summary.95% confidence

Sub-Topics Prescription Drugs

Track

in committee · New Jersey · General Assembly Jan 13, 2026

A 3512: Establishes "Equitable Drug Pricing and Patient Access Act."

This bill (A 3512) sets new reimbursement rules for pharmacies serving Medicaid patients in New Jersey. It requires pharmacies to be paid at least the national average drug cost plus a $10.92 dispensing fee, regardless of whether services are delivered through traditional Medicaid or managed care plans. The bill also mandates that Medicaid managed care plans must allow patients to choose any participating pharmacy and prohibits plans from unfairly blocking pharmacies from joining their networks. Additionally, it requires an audit to track pharmacy pricing and potential state savings from these changes. The law directly affects Medicaid beneficiaries, pharmacies, and Medicaid managed care organizations in New Jersey.

Topics ✓ Budget & TaxesSupports Budget & TaxesMandates higher Medicaid pharmacy reimbursements, increasing state spending on essential healthcare services within Medicaid program funding.85% confidence ✓ HealthcareSupports HealthcareMandates fair pharmacy reimbursement for Medicaid patients, ensures patient choice of pharmacy, and prohibits unfair network restrictions - directly improving healthcare access and equity.95% confidence

Sub-Topics Audits & Accountability Medicaid Prescription Drugs

Track